It's easy to imagine a U.S. regulatory system that advances the latest cures and therapies and immediately reimburses for new life-saving technologies. But when the regulatory status quo often delays and even stifles innovation, researchers, patients, and drug and device companies find it difficult, try as they might, to realize what so easily can be imagined.